Analyst Price Targets — BOLT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 20, 2025 10:20 am | — | H.C. Wainwright | $7.00 | $5.75 | TheFly | Bolt Biotherapeutics assumed with a Buy at H.C. Wainwright |
| May 15, 2024 2:13 am | Daina Graybosch | Leerink Partners | $1.00 | $1.32 | StreetInsider | Leerink Partners Downgrades Bolt Biotherapeutics, Inc. (BOLT) to Market Perform 'on Uncertain Platform Outlook' |
Latest News for BOLT
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.57 per share versus the Zacks Consensus Estimate of a loss of $2.97. This compares to a loss of $4.46 per share a year ago.
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results Cash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027 REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel…
VANCOUVER, BC / ACCESS Newswire / June 12, 2026 / Bolt Metals Corp. ("Bolt" or the "Company") (CSE:BOLT)(OTCQB:PCRCF)(FSE:A3D8AK), is pleased to announce that, further to its press releases dated May 13, 2026, the letter of intent dated October 23, 2025, and the definitive option agreement dated May 12, 2026, as amended (the "Option Agreement"), with Max Iron Brazil Ltd. ("MaxIron"), an entity controlled by Max…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BOLT.
U.S. House Trading
No House trades found for BOLT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.